Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > REGULATORY
REGULATORY
- Citations in Guidelines to Be Prerequisite for Health Coverage of Off-Label Drugs under 1980 Notification
May 24, 2013
- New Rules to Promote Generic Drug Use by Welfare Recipients to Take Effect This Year
May 23, 2013
- MOF Official Expresses Caution on Perpetuation of New Drug Premium, Citing “Need for Continual Verification”
May 22, 2013
- MHLW Orders Marketing Authorization Holders of Careram/Kolbet to Issue a “Blue Letter”
May 21, 2013
- PM Abe Indicates that Next Fiscal Reform Plan Will Not Include Controls on Growth Rate of Social Security Spending
May 20, 2013
- NIBIO Establishes Center for Innovative Drug Discovery and Development, Appoints Yoichi Kurebayashi as Director
May 20, 2013
- 39 Companies Report Discontinuing Supplies of Generics within 5 Years: MHLW Survey
May 17, 2013
- Government Aims for 60% Generic Drug Share by End of FY2017; Some See Shortcomings in Roadmap
May 17, 2013
- Pharma Execs Call for Perpetuation of Premium at 1st Public-Private Dialogue under PM Abe’s Second Cabinet
May 16, 2013
- CSIMC Approves Listing of 15 New APIs/19 Products Including Pfizer’s Xeljanz with Expected Peak Sales of 59.7 Billion Yen
May 16, 2013
- 1st Committee on New Drugs to Discuss GLP-1 Agonist Lyxumia, Other New Drugs on May 24
May 15, 2013
- PMDA-WEST to Be Launched in Osaka in October to Undertake Consultation Services, GMP Inspections
May 13, 2013
- Generic Drug Makers Make Only about 20% of Bulk Drug Substances Available from Multiple Sources: Dr Muto of JSGM
May 7, 2013
- MHLW Approves 2 Cell Culture-Based New Influenza Vaccines
May 7, 2013
- PMDA Announces "International Vision and Roadmap"
May 7, 2013
- MEXT to Award Up to 100 Million Yen Each to 15 National University Hospitals that Lead in Generic Drug Use
May 2, 2013
- Application of New Price Reduction Rule for Long-listed Drugs Should Distinguish between Products Which Received or Did Not Receive Premium: Mr Kamoya of FPMAJ
May 1, 2013
- First Committee Recommends Approval for New Gout, Hyperuricemia Treatment, Antihypertensive Tape Formulation
May 1, 2013
- PMRJ Introduces “RS Expert Certification System”
April 30, 2013
- PAFSC’s Second Committee Recommends Approval for Chugai’s Breast Cancer Drug Perjeta, Others
April 26, 2013
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…